Business Wire

bit.bio Wins Landmark Patent Defence for Groundbreaking opti-ox™ Cell Programming Technology

The European Patent Office (EPO) upholds bit.bio's patent for its dual genomic safe harbour technology, opti-ox™, securing the broadest possible claims for programming of pluripotent stem cells (PSCs) ...
Nature

Powering the next generation of allogeneic therapies with precision cell reprograming

bit.bio is a synthetic biology company that uses its cell identity coding platform to reprogram induced pluripotent stem cells to create any human cell type. With its cell identity coding platform, ...
Business Insider

Synthego and bit.bio Expand Strategic Partnership to Build a Platform for the Development of Safer and More Efficient Genetic Engineering of Human Cells for Cell Therapies

Synthego to develop multiplexed and complex genetic engineering strategies, increasing the safety and speed at which bit.bio can engineer human cells for cell therapies. bit.bio aims to leverage ...
Nasdaq

bit.bio Announced as Inaugural Partner of Ginkgo Bioworks’ New Technology Network

The Ginkgo Technology Network brings together over 25 diverse partners across an array of capabilities including AI, genetic medicines, biologics, and manufacturing. As a Ginkgo Technology Network ...
ksn.com

BlueRock Therapeutics and bit.bio announce collaboration and option agreement for the discovery and manufacture of regulatory T cell (Treg) based therapies

Research collaboration leverages bit.bio's machine learning-powered discovery platform to identify transcription factor (TF) combinations for reprogramming induced pluripotent stem cells (iPSCs) into ...
Business Wire

bit.bio Wins Landmark Patent Defence for Groundbreaking opti-ox™ Cell Programming Technology

CAMBRIDGE, England--(BUSINESS WIRE)--bit.bio, the company coding human cells for novel cures and a pioneer in synthetic biology, today announces the successful defence of its foundational European ...